Research
Hormonal
GLP-1 receptor agonists (e.g., Semaglutide, Tirzepatide) and dual/triple agonists induce T2D remission primarily through significant weight loss and reduction of ectopic fat, with some direct beta-cell protective effects.
If you have prediabetes or early Type 2 Diabetes and struggle with weight, GLP-1 or GLP-1/GIP agonists (like Semaglutide or Tirzepatide) are highly effective at restoring normal blood sugar levels. These drugs work by reducing appetite and body weight, with some also having direct benefits on beta-cells. They are often used alongside lifestyle changes.
StrongSupportsVERY_HIGH confidence
Recently, the therapeutic armamentarium in the field of diabetology has been enriched with new antihyperglycemic drugs with considerable efficacy in reducing body weight, which could play a pathogenetic role in the remission of T2D, not through the classical incretin effect, but by improving adipose tissue functions.
Why this rating
Supported by multiple large RCTs (STEP, SCALE, SURMOUNT).
Source
Remission of type 2 diabetes: position statement of the Italian society of diabetes (SID)
Danila Capoccia et al. · Acta Diabetologica · 2024
DOI 10.1007/s00592-024-02317-x
narrative_reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Type 2 diabetes remission is achievable through significant weight loss (specifically targeting ectopic fat in the liver and pancreas) via very low-calorie diets or bariatric surgery, challenging the view that T2D is an irreversible progressive disease.Strong
- Bariatric surgery (Metabolic Bariatric Surgery) is the most effective intervention for achieving long-term Type 2 Diabetes remission, with remission rates up to 80% in the first two years, driven by both weight loss and weight-independent hormonal changes.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →